DGAP-News: MeVis Medical Solutions AG / Key word(s): 9-month figures/Interim Report MeVis Medical Solutions AG: MeVis Q3 2015: Previous trend continued 19.11.2015 / 09:30 --------------------------------------------------------------------- Significant increase in revenues from strong US dollar - Sales in the third quarter increased by 33 % to EUR 4.8 m primarily due to the strong US dollar (prev. year: EUR 3.6 m) - Earnings before interest and taxes (EBIT) increased to EUR 3.6 m after nine month (prev. year EUR 3.2 m), EBIT margin of 30 % - Net profit declined cumulatively by EUR 0.5 m to EUR 3.0 m - Liquidity of EUR 22.0 m as at September 30, 2015 (Dec. 31, 2014: EUR 17.5 m) - Domination and profit and loss transfer agreement legally effective Bremen, November 19, 2015 - MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading provider of medical imaging software, today announced its results for the first three quarters of 2015. Sales generated in the third quarter of 2015 amounted to EUR 4,795 k, a significant 33 % higher than in the corresponding quarter of 2014 (EUR 3,599 k). Thus, in the first nine month sales increased considerably year on year to EUR 11,933 (prev. year: EUR 9,661 k). The growth in sales of EUR 2,272 is largely attributable to the changes of the US dollar, which contributed EUR 1,781 k to sales growth. Software development services totaling EUR 522 k (prev. year: EUR 0 k) following the agreement concluded with Hologic in September 2014 are also included in sales for the first nine months of 2015. Including the positive effect of the strong US dollar, sales in the new license business improved by 16 % to EUR 5,901 k, while sales in the maintenance business grew by 19 % to EUR 5,093 k, accounting for 43 % of total sales. Sales in the Digital Mammography segment were up by 30 % to EUR 9,454 k (prev. year: EUR 7,280 k), while sales in the Other Diagnostics segment grew slightly by 4 % to EUR 2,479 k (prev. year: EUR 2,381 k). Staff costs increased in the third quarter according to plan by 5 % to EUR 1,735 k (prev. year: EUR 1,641 k), resulting in an cumulative increase of 3 % (from EUR 5,370 k to EUR 5,208 k) for the first nine month. Primarily due to increased consulting costs in connection with the domination and profit and loss transfer agreement, other operating expenses rose in the third quarter in a year on year comparison to EUR 916 k (prev. year: EUR 572 k), and, cumulated for the first nine months of 2015, increased by 24 %. The capitalization of development expenses was ceased in the fourth quarter of 2014 (prev. year: EUR 1,163 k). Despite the discontinued capitalization of development costs, cumulated EBITDA (earnings before interest, taxes, depreciation and amortization) increased considerably by 17 % year on year from EUR 4,373 k to EUR 5,109 k. After depreciation and amortization of EUR 1,489 k (up 22 % year on year), this results in an EBIT (earnings before interest and taxes) of EUR 3,620 k (with 15 % well above the previous period's figure of EUR 3,150), corresponding to an EBIT margin of 30 % (prev. year: 33 %). The net financial result decreased by EUR 172 k year on year to EUR 603 k. At the same time, the slight improvement in earnings at MeVis BreastCare GmbH & Co. KG was overcompensated by effects from the development of the US dollar. Tax expenses increased by EUR 790 k to EUR 1,259 k, which is largely due to deferred taxes. After-tax earnings consequently fell by EUR 492 k to EUR 2,964 k, which is equivalent to undiluted earnings per share of EUR 1.66 (prev. year: EUR 2.01). Cash and cash equivalents rose by EUR 4,531 k to EUR 22,042 k as of September 30, 2015 compared to the end of 2014. This includes EUR 1,707 k from the disposal of treasury shares to VMS Deutschland Holdings GmbH in April 2015. The domination and profit and loss transfer agreement concluded on August 10, 2015 between the VMS Deutschland Holdings GmbH as the controlling company and MeVis Medical Solutions AG as the controlled company was registered with the Commercial Register of the Bremen Local Court on October 20, 2015 and thus became legally effective. The shareholders of the MeVis Medical Solutions AG already approved the domination and profit and loss transfer agreement by a large majority in the extraordinary general meeting on September 29, 2015. "We are pleased about the exceptionally strong sales in the third quarter and thus, the continuation of the positive trend of the first two quarters." Said Mr. Kirchhoff, CEO of MeVis Medical Solutions AG. Dr. Robert Hannemann, CFO of MeVis Medical Solutions AG, added: "Revenue growth is mainly, but not exclusively, attributable to the strong US dollar. The dependency on our anticipated declining business with Hologic remains high and has increased further in the third quarter." The Company's financial reports can be downloaded from the following website: http://www.mevis.de/en/investor-relations/financial-reports/ --------------------------------------------------------------------- 19.11.2015 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: MeVis Medical Solutions AG Caroline-Herschel-Str. 1 28359 Bremen Germany Phone: +49 421 224 95 0 Fax: +49 421 224 95 999 E-mail: ir@mevis.de Internet: http://www.mevis.de ISIN: DE000A0LBFE4 WKN: A0LBFE Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart End of News DGAP News Service --------------------------------------------------------------------- 414601 19.11.2015
DGAP-News: MeVis Medical Solutions AG: MeVis Q3 2015:
Top 10 Most Recent News Articles
Ampace Focuses on Battery Safety Standards at RE+ 2026
Battery Safety Takes Center Stage No mystery here: the safety of our beloved lithium-ion batteries is crucial, especially as AI data centers sprout like weeds. At RE+ 2026, Ampace is putting its chips on the table by spotlighting this hot topic. Dr. Drew Feng, their Chief Safety Officer, is set to reveal the big guns: findings from the PU100 large-scale fire test. Mark...
Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle
IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...
Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?
A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...
Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough
Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...
Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data
Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...
Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss
Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...
Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup
An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....
Continue Reading
Sungrow's Keeper Family: Revolutionizing C&I Energy Storage
The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...
Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake
Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...
Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026
A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...
Continue ReadingTop 5 Most Recently Viewed Articles
Beyond Meat Partners with Hard Rock Cafe for Burger Launch
Beyond Meat and Hard Rock Cafe Collaboration Beyond Meat, Inc. (NASDAQ: BYND), an innovator in plant-based proteins, is excited to announce a partnership with Hard Rock Cafe, introducing the newest Beyond Burger across all its North American locations. This initiative allows diners to swap any beef burger from Hard Rock's core and kids' menus for the delicious and...
Continue Reading
ATEC Water Systems Welcomes Industry Leader Steve Green
ATEC Water Systems welcomed Steve Green as their new Chief Commercial Officer back in 2024, shaking things up under the Cadiz, Inc. (NASDAQ: CDZI) umbrella. Traders watched closely; this wasn't just a run-of-the-mill hire but rather a strategic move aimed at revitalizing the company's trajectory in a crowded market. With Steve's extensive background in the water industry,...
Continue Reading
Mission Critical Group Welcomes Mark Feasel as VP of Sales
Mission Critical Group Appoints New Vice President of Sales Mission Critical Group (MCG), a leader in critical power infrastructure solutions, is excited to announce the appointment of industry veteran Mark Feasel as the Vice President of Sales in the Commercial and Innovation Division. With this strategic addition, MCG aims to enhance its sales strategy and broaden its...
Continue Reading
Ascot Resources Explores Alternative TSXV Listing Options
Ascot Resources Faces Delisting from TSX Ascot Resources Ltd., a Canadian mining company headquartered in Vancouver, is going through significant changes regarding its stock listings. Recently, the Continued Listing Committee of the Toronto Stock Exchange (TSX) informed Ascot that its common shares are set to be delisted at the market's close on a specified date. This...
Continue Reading
Albany International Corporation Faces Legal Scrutiny Amid Stockholder Concerns
Introduction to the Investigation Albany International Corporation is currently experiencing legal scrutiny as concerns arise among stockholders regarding the company's financial performance. Recently, the law firm Bragar Eagel & Squire, P.C. has stepped in, urging investors who may have suffered losses in Albanian stocks to reach out for assistance. The firm seeks to...
Continue Reading